About: Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 2000 (uk) article scientifique publié en juillet 2000 (fr) im Juli 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 2000 (ast) scientific article published on 01 July 2000 (en)
publication date	wds:Q74180227-F335D242-4419-47D0-840A-0897215935AB
publication date	2000-07-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q74180227-05577E02-F7B5-4A8A-85E4-1872C94C19AD wds:Q74180227-810E5DBC-25AD-4649-B675-0C07E65A5476 wds:Q74180227-83E886FA-A908-4AC4-BF13-97CF953D0182 wds:Q74180227-C1F055DD-1502-4ED3-A086-6E326BD4697B wds:Q74180227-C86653F0-30C5-48CD-A872-7FD9936FF5C6 wds:Q74180227-D3F9F285-4B66-40DD-AC20-240ACCEDA81B wds:Q74180227-D4D13C2E-47BA-4651-9EDB-8D67CFFA2435 wds:Q74180227-EC671FE6-E21D-4D4D-94C2-A36CA08B6A1C wds:Q74180227-F74FEECF-1A99-4A05-8F50-51390C6A9EF7 wds:Q74180227-F8987FC4-8718-4064-8C5C-92E7A3BE51BD
author name string	Oertel R Zschiesche M Kroemer HK Siegmund W Westphal K Terhaag B Franke G Weinbrenner A Giessmann T Stuhr M
rdfs:label	Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (en) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (nl)
skos:prefLabel	Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (en) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (nl)
name	Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (en) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (nl)
title	wds:Q74180227-31E0CEBC-9288-4E87-BBFD-2E1D7AD4F4D9
title	Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein (en)
page(s)	wds:Q74180227-63F42DAF-904C-4FCF-AFE6-24AB3E16714A
page(s)	6-12
instance of	wds:Q74180227-F434E867-70B6-40D7-B6B6-55CD26CD90E2
instance of	scholarly article
main subject	wds:Q74180227-85AADAB3-0B89-477E-B7F5-80CCE309332D
main subject	bioavailability
PubMed ID	wds:Q74180227-A1F93E64-775D-45B2-BD88-B79A1869C3A6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10945310
PubMed ID	10945310
published in	wds:Q74180227-4223EC0B-4D34-4141-A0CC-681344483DA8
published in	Clinical Pharmacology & Therapeutics
issue	wds:Q74180227-1B1062BC-CBEC-4BE6-981D-EEB393FE5FEE
volume	wds:Q74180227-580A5BDF-76B3-4C14-829E-DFFE7294F1A7
issue	1
volume	68
DOI	wds:Q74180227-EC6CA3CD-17A9-4388-B447-ED15D60ED34F
DOI	http://dx.doi.org/10.1067/MCP.2000.107579
DOI	10.1067/MCP.2000.107579
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74180227
is cites work of	The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males Fluorescence polarization assays in small molecule screening pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug Prediction of intestinal permeability In vitro P-glycoprotein affinity for atypical and conventional antipsychotics Antihypertensive therapy: special focus on drug interactions Dietary Effects on Drug Metabolism and Transport Improving cancer chemotherapy with modulators of ABC drug transporters Clinical pharmacokinetics of ranolazine The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives Psychotropic drug-drug interactions involving P-glycoprotein Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies Construction of a functional transporter analysis system using MDR1 knockdown Caco-2 cells Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia Pharmacokinetic Interaction Study of Ranitidine and Daijokito in Healthy Volunteers Effect of green tea catechins on the pharmacokinetics of digoxin in humans. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?
is cites work of	wds:Q35750597-C2AC1606-76F1-4660-BFE9-9FC1CD6DBFE6 wds:Q92670372-6BA844CB-BE0F-41A9-BF0C-0E8CE66EC4EE wds:Q35178549-CBB0EA8D-BD5B-4A30-9CAE-8E9D2BBCA480 wds:Q46252123-1AF6E055-6FBC-48FF-8931-164622654225 wds:Q34581541-B2A61A3E-8D30-4AC3-BF35-C059BC49DBB5 wds:Q37696435-729257E0-0668-483B-8344-23158EFF819C wds:Q27692687-75459F3F-F916-405D-85B2-E6D8F8DEC075 wds:Q46261836-A82301FB-79E7-4EFB-97DA-ECBC68D4F212

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software